Report ID: SQMIG35D2142
Report ID:
SQMIG35D2142 |
Region:
Global |
Published Date: December, 2024
Pages:
157
|
Tables:
63 |
Figures:
75
Medical Affairs Outsourcing Market size was valued at USD 1.92 Billion in 2023 and is poised to grow from USD 2.18 Billion in 2024 to USD 6.05 Billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).
The global medical affairs outsourcing market is experiencing substantial growth driven by a surge in clinical trials resulting from the rising prevalence of both communicable and non-communicable diseases.
This heightened clinical trial activity has led to increased demand for medical devices and novel drugs, thus fueling the need for medical outsourcing services.
Additionally, the market is bolstered by the attractive combination of cost-effective and high-quality services provided by contract research organizations, as well as stringent regulatory requirements that necessitate specialized expertise.
Together, these factors create a conducive environment for the expansion and advancement of the medical affairs outsourcing market. The global pandemic's impact has been far-reaching, affecting almost every industry, including medical affairs outsourcing.
Despite the challenges faced by regulatory and outsourcing teams, the COVID-19 outbreak has compelled a change in the work schedule of medical affairs professionals in the pharmaceutical industry. This has led to a significant increase in virtual scientific interactions and a higher priority placed on scientific communication. In the long term, these shifts are expected to reshape the structure and responsibilities of medical affairs teams.
New areas, such as facilitating access to advanced treatments in specific healthcare channels, engaging with patient groups, and playing essential roles in specialty care, are anticipated to become integral to the medical affairs function.
The pharmaceutical and medical device industries are facing pricing pressures, stringent regulations, and patent expirations, which have resulted in shrinking profit margins. As a strategic competitive tool, contract medical affairs services are gaining prominence among biopharmaceutical and pharmaceutical companies as they offer cost savings.
By outsourcing medical affairs services to contract research organizations (CROs), pharmaceutical and medical device firms can reduce operational costs, limit liability exposure, enhance regulatory compliance, and prevent process delays through collaboration with well-trained outsourcing partners. This trend is likely to continue as companies seek to optimize their operations and navigate the challenging business landscape.
US Medical Affairs Outsourcing Market is poised to grow at a sustainable CAGR for the next forecast year.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35D2142